Neurocognitive outcomes of children with osteosarcoma treated with methotrexate

Affiliations

¹ Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
² Division of Health and Behavioral Sciences, St. Luke's International University, Tokyo, Japan.
³ Department of Data Management, National Center for Child Health and Development, Tokyo, Japan.

Haruko Shima et al. Pediatr Int. 2023 Jan.

. 2023 Jan;65(1):e15487.

doi: 10.1111/ped.15487.

¹ Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
² Division of Health and Behavioral Sciences, St. Luke's International University, Tokyo, Japan.
³ Department of Data Management, National Center for Child Health and Development, Tokyo, Japan.

No abstract available

Keywords: children; late effects; methotrexate; neurocognitive outcomes; osteosarcoma.

References

1. Daetwyler E, Bargetzi M, Otth M, Scheinemann K. Late effects of high-dose methotrexate treatment in childhood cancer survivors-a systematic review. BMC Cancer. 2022;22:267.
1. Iyer NS, Balsamo LM, Bracken MB, Kadan-Lottick NS. Chemotherapy-only treatment effects on long-term neurocognitive functioning in childhood ALL survivors: a review and meta-analysis. Blood. 2015;126:346-53.
1. Edelmann MN, Daryani VM, Bishop MW, Liu W, Brinkman TM, Stewart CF, et al. Neurocognitive and patient-reported outcomes in adult survivors of childhood osteosarcoma. JAMA Oncol. 2016;2:201-8.
1. Feng S, Cen J, Huang Y, Shen H, Yao L, Wang Y, et al. Matrix metalloproteinase-2 and -9 secreted by leukemic cells increase the permeability of blood-brain barrier by disrupting tight junction proteins. PLoS One. 2011;6:e20599.
1. Jacola LM, Conklin HM, Krull KR, Pei D, Cheng C, Reddick WE, et al. The impact of intensified CNS-directed therapy on neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia treated without cranial irradiation. J Clin Oncol. 2022;40(36):4218-27.